Diagnosis and Management of Small Fiber Neuropathy

Pathophysiological Characteristics

• The small fibers constitute 79.6% to 91.4% of the peripheral nerve fibers, with Aδ fibers being finely myelinated and C fibers being unmyelinated, both responsible for pain and temperature perception 1, 2
• Small fiber neuropathy cannot be detected by conventional nerve conduction studies, which primarily assess large fiber function 3, 4

Clinical Presentation

• Patients with small fiber neuropathy typically present with distal, symmetric, and nocturnally exacerbated neuropathic pain, described as burning, tingling, or shooting pain 1
• Autonomic dysfunction, including postural hypotension, bladder disturbances, and reduced heart rate variability, is observed in approximately 70% of patients 3
• Sudomotor dysfunction contributes to plantar ulceration in diabetic patients 1

Diagnostic Approach

• Skin biopsy with quantification of intraepidermal nerve fiber density (IENFD) is the gold standard for diagnosis, especially when nerve conduction studies are normal, with a sensitivity of 77.2-88% and specificity of 79.6-88.8% 4, 5
• Quantitative sensory testing (QST) for thermal thresholds complements skin biopsy, while tests of autonomic function, such as QSART, document small fiber dysfunction with high sensitivity 4
• A cutoff point of ≤8.8 fibers/mm at the ankle demonstrates good accuracy for diagnosis 5

Diagnostic Pitfalls

• Relying solely on nerve conduction studies may lead to missed diagnoses, as these tests only evaluate large fiber function 4
• Damage to small fibers often precedes damage to large fibers in diabetic neuropathy, and IENFD is significantly reduced in diabetic patients even with normal nerve conduction studies 1, 4, 5

Management Considerations

• Avoiding excessive cooling of extremities is recommended, as it may worsen tissue damage and lead to ulcerations 4
• Repeated skin biopsies may be considered in selected cases to monitor disease progression or response to treatment 4
• Rigorous glycemic control is essential to prevent disease progression in diabetic patients 4

Treatment for Small Fiber Neuropathy

Treatment Strategy Based on Etiology

• The American Diabetes Association recommends optimizing glycemic control immediately as the primary disease-modifying intervention to prevent development in type 1 diabetes and slow progression in type 2 diabetes 6
• The American Diabetes Association suggests initiating pregabalin, duloxetine, or gabapentin as first-line agents for neuropathic pain management in diabetic small fiber neuropathy 6
• The European Respiratory Society recommends considering intravenous immunoglobulin (IVIg) either alone or with anti-TNF therapy for patients with sarcoidosis-related small fiber neuropathy, with 75% of patients deriving symptomatic benefit from IVIg dosing regimens 7
• The European Respiratory Society suggests that anti-TNF monoclonal antibodies (infliximab or adalimumab) may provide benefit for patients with sarcoidosis-related small fiber neuropathy, though the magnitude of effect is difficult to quantify from available retrospective data 7

Critical Non-Pharmacologic Management

• The Mayo Clinic recommends engaging in usual lifestyle activities as much as possible while minimizing known triggers, and continuing exercise and normal daily activities to prevent progression to debilitating chronic pain syndrome 8
• The Mayo Clinic advises against using excessive cooling of extremities for pain relief, as this worsens tissue damage and can lead to ulcerations 8

Intraepidermal Nerve Fiber Density (IENFD) as a Prognostic Marker in Diabetic Small‑Fiber Neuropathy

Correlation of IENFD with Disease Severity

• In diabetic patients, IENFD declines progressively as the severity of small‑fiber neuropathy increases, showing an inverse relationship with neurological disability scores. 9

Pain Phenotype and IENFD

• Individuals with diabetic painful neuropathy exhibit lower IENFD compared with those who have painless neuropathy. 9

Potential for Reversal with Intervention

• A 12‑month program of diet and exercise in people with small‑fiber neuropathy and glucose intolerance led to an increase in IENFD, demonstrating that appropriate lifestyle intervention can promote nerve regeneration. 9

Limited Regeneration after Transplantation

• No measurable change in IENFD was detected after pancreas‑kidney transplantation in a cohort of diabetic patients, suggesting that early, substantial loss of small fibers may limit rapid regenerative response. 9

Temporal Sequence of Fiber Involvement

• Small‑fiber damage commonly precedes large‑fiber involvement in diabetic neuropathy; therefore, normal nerve‑conduction studies do not exclude ongoing disease progression. 9

Impact of Diabetic Neuropathy on Itch‑Mediating C Fibers

Anatomical and Pathophysiological Basis

• Small unmyelinated C fibers represent roughly 80 %–91 % of all peripheral nerve fibers and convey pain, temperature, and itch sensations. 10
• In diabetic neuropathy, these small C fibers are damaged early and preferentially, often before any abnormality is detectable on conventional large‑fiber nerve conduction studies. 10

Diagnostic Implications

• Small‑fiber dysfunction may be present in individuals with impaired glucose tolerance or diabetes even when standard electrophysiological tests are completely normal. 10
• Quantitative sensory testing of thermal thresholds can document functional impairment of small C fibers in diabetic patients. 10

Clinical Consequences

• The coexistence of small‑fiber sensory loss and autonomic (sudomotor) dysfunction markedly increases the risk of foot ulceration, affecting approximately 10 %–20 % of diabetic individuals. 10

Mechanistic Understanding of C‑Fiber‑Mediated Itch

• Activation of nociceptive C fibers triggers an axon‑reflex that conducts signals orthodromically to the spinal cord and antidromically to adjacent axonal branches. 11
• The antidromic component of the axon‑reflex releases vasoactive neuropeptides such as substance P and calcitonin gene‑related peptide, producing vasodilation and increased vascular permeability. 11
• In patients with diabetic neuropathy, this neurovascular response is attenuated and correlates with other measures of nerve function. 11